 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE has received guidance from the US Food and Drug Administration FDA on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome FXS. The trial, which will be called RECONNECT A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome, is designed to evaluate the efficacy and safety of Zygel in children and adolescents with FXS. 